After-Hours Movers 12/26: (TCON) (ROKU) (AAPL)

December 26, 2018 5:11 PM

TRACON Pharmaceutical (NASDAQ: TCON) +38%; today announced positive top-line clinical results from a Phase 1 study of TRC105 and Opdivo® (nivolumab) for the treatment of non-small cell lung cancer.

Roku (NASDAQ: ROKU) +2%; gained 12 percent Wednesday as tech surged, earlier named top pick for 2019 at Needham.

Apple (NASDAQ: AAPL) -0.4%; climbed 7 percent earlier.

Categories

Special Reports